“T1D often starts at a very young age, and it’s a relentless, around-the-clock disease that requires frequent monitoring and tailoring insulin dosing throughout the day,” he says. “This constant attention impacts patients and their families. I’d love to be able to wave a magic wand and make it go away. That’s what motivates my research.”
Dr. Griffin recently joined BRI’s team and will conduct some exciting T1D research. We asked a few questions about his background and the studies he’ll take on at BRI.
